CenterPoint Energy, Inc. (CNP) Analysts See $0.20 EPS, Matthews International Capital Management Lowered China Biologic Prods (CBPO) Stake By $1.21 Million

July 21, 2017 - By Marguerite Chambers

Matthews International Capital Management Llc decreased China Biologic Prods Inc (CBPO) stake by 31.74% reported in 2016Q4 SEC filing. Matthews International Capital Management Llc sold 11,300 shares as China Biologic Prods Inc (CBPO)’s stock rose 0.78%. The Matthews International Capital Management Llc holds 24,300 shares with $2.61 million value, down from 35,600 last quarter. China Biologic Prods Inc now has $2.77B valuation. The stock declined 0.37% or $0.39 reaching $103.9 per share. About 90,088 shares traded. China Biologic Products Inc (NASDAQ:CBPO) has declined 1.48% since July 21, 2016 and is downtrending. It has underperformed by 18.18% the S&P500.

Analysts expect CenterPoint Energy, Inc. (NYSE:CNP) to report $0.20 EPS on August, 3 before the open.They anticipate $0.03 EPS change or 17.65% from last quarter’s $0.17 EPS. CNP’s profit would be $87.50 million giving it 35.09 P/E if the $0.20 EPS is correct. After having $0.37 EPS previously, CenterPoint Energy, Inc.’s analysts see -45.95% EPS growth. About 805,949 shares traded. CenterPoint Energy, Inc. (NYSE:CNP) has risen 25.54% since July 21, 2016 and is uptrending. It has outperformed by 8.84% the S&P500.

Since April 3, 2017, it had 0 insider buys, and 3 selling transactions for $84,470 activity. Another trade for 1,000 shares valued at $28,350 was sold by Prochazka Scott M.

CenterPoint Energy, Inc. is a public utility holding company. The company has market cap of $12.28 billion. The Company, through its subsidiaries, owns and operates electric transmission and distribution facilities, and natural gas distribution facilities. It has a 25.92 P/E ratio. The Electric Transmission & Distribution segment provides electric transmission and distribution services to retail electric providers.

Among 11 analysts covering CenterPoint (NYSE:CNP), 1 have Buy rating, 0 Sell and 10 Hold. Therefore 9% are positive. CenterPoint had 22 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of CenterPoint Energy, Inc. (NYSE:CNP) earned “Hold” rating by Deutsche Bank on Tuesday, August 11. As per Tuesday, October 13, the company rating was upgraded by Credit Suisse. J.P. Morgan downgraded it to “Hold” rating and $2900 target in Thursday, June 29 report. The stock of CenterPoint Energy, Inc. (NYSE:CNP) has “Neutral” rating given on Monday, May 9 by Goldman Sachs. SunTrust maintained the shares of CNP in report on Monday, September 26 with “Neutral” rating. Deutsche Bank maintained CenterPoint Energy, Inc. (NYSE:CNP) rating on Thursday, May 12. Deutsche Bank has “Hold” rating and $22.50 target. Goldman Sachs downgraded CenterPoint Energy, Inc. (NYSE:CNP) on Monday, October 19 to “Sell” rating. The stock of CenterPoint Energy, Inc. (NYSE:CNP) has “Buy” rating given on Tuesday, January 12 by Argus Research. The stock of CenterPoint Energy, Inc. (NYSE:CNP) earned “Neutral” rating by SunTrust on Monday, March 7. The firm has “Buy” rating by Argus Research given on Thursday, March 24.

Investors sentiment decreased to 1.18 in Q4 2016. Its down 0.18, from 1.36 in 2016Q3. It dropped, as 43 investors sold CenterPoint Energy, Inc. shares while 145 reduced holdings. 63 funds opened positions while 158 raised stakes. 314.67 million shares or 0.98% more from 311.63 million shares in 2016Q3 were reported. Barnett Communications reported 500 shares. Rothschild Asset Management Incorporated reported 0.01% in CenterPoint Energy, Inc. (NYSE:CNP). Wellington Mngmt Group Ltd Liability Partnership holds 0% or 441,231 shares. Sei Invests has 63,230 shares for 0.01% of their portfolio. Paloma Prtn reported 0.02% in CenterPoint Energy, Inc. (NYSE:CNP). Manufacturers Life Insurance The reported 0.1% of its portfolio in CenterPoint Energy, Inc. (NYSE:CNP). Kennedy Capital Management Incorporated has 0.1% invested in CenterPoint Energy, Inc. (NYSE:CNP). The Switzerland-based Swiss Financial Bank has invested 0.04% in CenterPoint Energy, Inc. (NYSE:CNP). Moreover, Contravisory Inv Mngmt has 0.01% invested in CenterPoint Energy, Inc. (NYSE:CNP). Advsrs Asset holds 1.11M shares. Ing Groep Nv invested in 0.03% or 72,791 shares. Cipher Cap Limited Partnership holds 0.38% or 233,141 shares in its portfolio. Dupont Cap owns 351,668 shares for 0.19% of their portfolio. Capstone Asset Mgmt holds 61,014 shares. Numeric Invsts Lc invested 0.71% of its portfolio in CenterPoint Energy, Inc. (NYSE:CNP).

Investors sentiment decreased to 0.73 in Q4 2016. Its down 1.04, from 1.77 in 2016Q3. It fall, as 30 investors sold CBPO shares while 51 reduced holdings. 14 funds opened positions while 45 raised stakes. 18.07 million shares or 1.23% less from 18.29 million shares in 2016Q3 were reported. Lazard Asset Mngmt Lc stated it has 0% of its portfolio in China Biologic Products Inc (NASDAQ:CBPO). Investec Asset Mngmt North America holds 0.86% of its portfolio in China Biologic Products Inc (NASDAQ:CBPO) for 53,371 shares. Prudential has invested 0% of its portfolio in China Biologic Products Inc (NASDAQ:CBPO). The Illinois-based Envestnet Asset has invested 0.01% in China Biologic Products Inc (NASDAQ:CBPO). Mirae Asset Global Invs Limited owns 0.91% invested in China Biologic Products Inc (NASDAQ:CBPO) for 379,776 shares. Raymond James & Associates has invested 0% in China Biologic Products Inc (NASDAQ:CBPO). Blackrock Grp Ltd stated it has 0.01% of its portfolio in China Biologic Products Inc (NASDAQ:CBPO). Renaissance Technology Ltd Liability Corp accumulated 146,496 shares. Geode Capital Mgmt Ltd Company owns 12,403 shares for 0% of their portfolio. Jupiter Asset Mgmt holds 0.18% or 44,669 shares. Agf Invs reported 120,663 shares. Research Investors, California-based fund reported 3.26 million shares. Gsa Cap Prtn Limited Liability Partnership reported 23,837 shares or 0.15% of all its holdings. Mitsubishi Ufj Tru holds 0.01% or 65,270 shares in its portfolio. Trexquant Inv Limited Partnership holds 4,300 shares or 0.07% of its portfolio.

Among 2 analysts covering China Biologic Products (NASDAQ:CBPO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. China Biologic Products had 3 analyst reports since September 4, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Monday, June 12 report. The stock of China Biologic Products Inc (NASDAQ:CBPO) earned “Buy” rating by Jefferies on Friday, September 4.

Since February 28, 2017, it had 0 insider purchases, and 3 selling transactions for $14.63 million activity. $2.02M worth of China Biologic Products Inc (NASDAQ:CBPO) was sold by Shao Sean on Wednesday, March 1. Shares for $873,638 were sold by Liu Zhijing CBPO. $11.74M worth of China Biologic Products Inc (NASDAQ:CBPO) was sold by Gao David.

Analysts await China Biologic Products Inc (NASDAQ:CBPO) to report earnings on August, 3. They expect $1.36 earnings per share, up 23.64% or $0.26 from last year’s $1.1 per share. CBPO’s profit will be $36.26M for 19.10 P/E if the $1.36 EPS becomes a reality. After $1.32 actual earnings per share reported by China Biologic Products Inc for the previous quarter, Wall Street now forecasts 3.03% EPS growth.